Randomized trial demonstrates significant tumor load reduction with SIRPαFc in Sézary syndrome, indicating that CD47 blockade provides therapeutic benefit.
Key Points
To investigate the expression, clinical significance, and therapeutic targeting of CD47 using the novel decoy receptor SIRPαFc in Sézary syndrome.
Analyzed CD47 expression in Sézary cells from peripheral blood and skin lesions, evaluating regulation by interleukin 4 (IL-4), IL-7, and IL-13.
Assessed macrophage-mediated phagocytosis in vitro and evaluated tumor load reduction in a registered clinical trial (NCT02663518) administering SIRPαFc (TTI-621).
High CD47 expression was identified on Sézary cells in both peripheral blood and skin, which significantly correlated with worse overall survival.
Administration of SIRPαFc (TTI-621) stimulated macrophage-mediated phagocytosis of malignant cells and produced significant tumor load reduction in clinical trial participants.